Table 1.
Baseline characteristics
| Placebo (n = 228) |
Empagliflozin 10 mg (n = 224) |
Empagliflozin 25 mg (n = 224) |
Sitagliptin 100 mg (n = 223) |
Total (N = 899) |
|
|---|---|---|---|---|---|
| Male | 123 (53.9) | 142 (63.4) | 145 (64.7) | 141 (63.2) | 551 (61.3) |
| Age (years) | 54.9 ± 10.9 | 56.2 ± 11.6 | 53.8 ± 11.6 | 55.1 ± 9.9 | 55.0 ± 11.0 |
| Race | |||||
| Asian | 146 (64.0) | 143 (63.8) | 144 (64.3) | 143 (64.1) | 576 (64.1) |
| White | 76 (33.3) | 77 (34.4) | 73 (32.6) | 76 (34.1) | 302 (33.6) |
| Black/African-American | 6 (2.6) | 3 (1.3) | 7 (3.1) | 3 (1.3) | 19 (2.1) |
| Other | 0 | 1 (0.4) | 0 | 1 (0.4) | 2 (0.2) |
| Time since diagnosis of T2DM (years) | |||||
| ≤1 | 72 (31.6) | 87 (38.8) | 91 (40.6) | 93 (41.7) | 343 (38.2) |
| >1–5 | 104 (45.6) | 92 (41.1) | 83 (37.1) | 86 (38.6) | 365 (40.6) |
| >5–10 | 33 (14.5) | 29 (12.9) | 37 (16.5) | 32 (14.3) | 131 (14.6) |
| >10 | 19 (8.3) | 16 (7.1) | 13 (5.8) | 12 (5.4) | 60 (6.7) |
| Body weight (kg) | 78.2 ± 19.9 | 78.4 ± 18.7 | 77.8 ± 18.0 | 79.3 ± 20.4 | 78.4 ± 19.2 |
| Body mass index (kg/m2) | 28.7 ± 6.2 | 28.3 ± 5.5 | 28.2 ± 5.5 | 28.2 ± 5.2 | 28.4 ± 5.6 |
| HbA1c (%) | 7.91 ± 0.78 | 7.87 ± 0.88 | 7.86 ± 0.85 | 7.85 ± 0.79 | 7.88 ± 0.82 |
| FPG (mmol/l) | 8.6 ± 2.0 | 8.5 ± 1.8 | 8.5 ± 1.9 | 8.2 ± 1.6 | 8.4 ± 1.8 |
| SBP (mmHg) | 130.4 ± 16.3 | 133.0 ± 16.6 | 129.9 ± 17.5 | 132.5 ± 15.8 | 131.4 ± 16.6 |
| DBP (mmHg) | 78.9 ± 9.6 | 79.2 ± 9.6 | 78.3 ± 9.4 | 80.1 ± 10.0 | 79.1 ± 9.6 |
| eGFR (ml/min/1.73 m2) (MDRD) | 86.8 ± 17.9 | 87.7 ± 19.2 | 87.6 ± 18.3 | 87.6 ± 17.3 | 87.4 ± 18.2 |
Data are n (%) or mean ± standard deviation in the full analysis set